User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

Primary tabs

Decaudin, Didier [] Mounier, Nicolas [] Tilly, Hervé [] Ribrag, Vincent [] Ghesquières, Hervé [] Bosly, André [UCL] Gisselbrecht, Christian []

This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas.

Bibliographic reference Decaudin, Didier ; Mounier, Nicolas ; Tilly, Hervé ; Ribrag, Vincent ; Ghesquières, Hervé ; et. al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.. In: Clinical lymphoma, myeloma & leukemia, Vol. 11, no. 2, p. 212-8 (2011)
Permanent URL http://hdl.handle.net/2078.1/111386